Job Syndrome

HOUSTON--( BUSINESS WIRE )--Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrotic diseases, chronic inflammatory diseases and diverse cancers, today announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics, was selected to make a presentation and co-lead a panel discussion at the 8 th Annual IPF Summit being held in Boston, MA on August 22, 2024. Presentation Title: Unveiling TTI-101 as a Novel Approach in Pulmonary Fibrosis & Interstitial Lung Disease Treatment Session: Examining the Future Directions of the Pulmonary Fibrosis Landscape to Bring Better Drugs to Patients Faster Date & Time: Thursday, August 22, 2024, at 3:45 PM ET Panel Discussion Title: Unravelling the Rationale Behind Combination Therapy & Critical Design & Development Considerations for Emerging Therapeutic Candidates Session: Looking Beyond Monotherapy & The Current Standard of Care to Combining Existing & Emerging Therapeutics for a Combination Approach Date & Time: Thursday, August 22, 2024, at 10:00 AM ET The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com . About Tvardi Therapeutics Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein that plays a central role in the pathogenesis of many fibrotic and inflammatory diseases. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: idiopathic pulmonary fibrosis ( NCT05671835 ) and hepatocellular carcinoma ( NCT05440708 ). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter) .

HOUSTON--( BUSINESS WIRE )--Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET. In addition to the fireside chat, the management team will hold one-on-one investor meetings Monday and Tuesday, August 5-6, 2024. If you are interested in meeting with the Tvardi Therapeutics management team during the conference, please reach out to BTIG . About Tvardi Therapeutics Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: hepatocellular carcinoma ( NCT05440708 ) and idiopathic pulmonary fibrosis ( NCT05671835 ). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter) .

NEW YORK, July 25, 2024 /PRNewswire/ -- The Job Research Foundation, which seeks to help find a cure for Job Syndrome, by providing the global scientific community with additional opportunities to further research into the rare multisystem immunodeficiency disorder, has announced the seventh round of grant funding. The Foundation will award up to two grants in the amount of $200,000 each over a two-year period for scientific research into the causes of, and treatments for, Job Syndrome. To date, the organization has funded a total of fifteen research projects across the world. Grant applications can be found online at . Deadline to apply is October 14, 2024. The long-term goal of the Foundation is to help advance research to find a cure for Job Syndrome. In the short term, the Foundation hopes the research will improve the treatments for patients suffering from the rare disorder. Special consideration will be given to research focused on Job Syndrome and Pulmonary Function. Previous applicants can apply in subsequent years to extend their research. The application process is open to researchers worldwide and awardees will be announced between December 2024 and January 2025. Job Research Foundation seeks to not only help find a cure for Job Syndrome by providing the scientific community with additional opportunities to further research into the disorder, but also hopes that investigators will research treatments to help those suffering with Job Syndrome. Also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), Job Syndrome was discovered in 1966 and is a rare multisystem immunodeficiency disorder found in males and females worldwide. Visit for additional details. MEDIA CONTACT: Risa B. Hoag, GMGPR, 845-627-3000, [email protected] SOURCE Job Research Foundation